Interventions for Tuberculosis Control and Elimination 2002
Interventions for Tuberculosis Control and Elimination 2002
Interventions for Tuberculosis Control and Elimination 2002
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
112. Van den Br<strong>and</strong>e P, van Steenbergen W, Vervoort G, Demedts M. Aging <strong>and</strong><br />
hepatotoxicity of isoniazid <strong>and</strong> rifampin in pulmonary tuberculosis.<br />
Crit Care Med 1995; 152: 1705-8.<br />
Am J Respir<br />
113. P<strong>and</strong>e JN, Singh SPN, Khilnani GC, T<strong>and</strong>on RK. Risk factors <strong>for</strong> hepatotoxicity<br />
from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-6.<br />
114. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid<br />
preventive therapy. A 7-year survey from a public health tuberculosis clinic.<br />
JAMA 1999; 281: 1014-8.<br />
115. Leonin TA, Julian EV, Baluis CR. A review of the hepatotoxic effects of anti-<br />
TB drugs at the Veterans Memorial Medical Center. Chest 1979; 11: 140-8.<br />
116. Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973; 79: 1-12.<br />
117. Lauterburg BH, Smith CV, Todo EL, Mitchell JR. Pharmacokinetics of the toxic<br />
hydrazino metabolites <strong>for</strong>med from isoniazid in humans.<br />
Therapeutics 1985; 235: 566-70.<br />
J Pharmacol Experim<br />
118. Gangadharam PRJ. Isoniazid, rifampin, <strong>and</strong> hepatotoxicity. (Editorial). Am<br />
Rev Respir Dis 1986; 133: 963-5.<br />
119. Martinez-Roig A, Cami J, Llorens-Terol J, de la Torre R, Perich F. Acetylation<br />
phenotype <strong>and</strong> hepatotoxicity in the treatment of tuberculosis in children.<br />
Pediatrics 1986; 77: 912-5.<br />
120. Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid,<br />
rifampicin <strong>and</strong> pyrazinamide. Tubercle 1978; 59: 13-32.<br />
121. Ellard GA, Girling DJ, Nunn AJ. The hepatotoxicity of isoniazid among three<br />
acetylator phenotypes. (Corrspondence). Am Rev Respir Dis 2001; 123: 568-70.<br />
122. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis<br />
undertaken by the British Medical Research Council <strong>Tuberculosis</strong> Units, 1946-<br />
1986, with relevant subsequent publications.<br />
(suppl 2): S231-S279.<br />
Int J Tuberc Lung Dis 1999; 3<br />
123. International Union Against <strong>Tuberculosis</strong> Committee on Prophylaxis. Efficacy<br />
of various durations of isoniazid preventive therapy <strong>for</strong> tuberculosis: five years<br />
of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-64.<br />
124. Askgaard DS, Wilcke T, Dossing M. Hepatotoxicity caused by the combined<br />
action of isoniazid <strong>and</strong> rifampicin. Thorax 1995; 50: 213-4.<br />
125. Campbell IA. Toxicity of isoniazid <strong>and</strong> rifampicin in combination.<br />
(Correspondence). Thorax 1994; 50: 814.<br />
126. Muakkassah SF, Bidlack WR, Yang WCT. Mechanism of the inhibitory action<br />
of isoniazid on microsomal drug metabolism.<br />
1651-8.<br />
Biochem Pharmacol 1981; 30:<br />
127. Baciewicz AM, Self TH. Isoniazid interactions. South Med J 1985; 78: 714-8.<br />
128. Kottegoda SR.<br />
1074.<br />
Cheese, wine, <strong>and</strong> isoniazid. (Correspondence). Lancet 1985; 2:<br />
178
Change language